Combination therapy • Trial completion date • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)
|
EGFR mutation • TMB-H • MSI-H/dMMR • ALK rearrangement
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • INBRX-106